Dr. Steven Treon, from the Dana-Farber Cancer Institute, is coming to Sarasota! Dr. Treon will be sharing an update on the current advances in clinical and laboratory research from the Bing Center for Waldenstrom’s Macroglobulinemia. Dr. Luis Chu, of Florida Cancer Specialists & Research Institute, Sarasota, will also be available for questions.

Professor Treon speaking to delegates of the 79th Annual Meeting of the Japanese Society of Hematology. One hundred and fifty delegates to the 79th Annual Meeting of the Japanese Society of Hematology attended a workshop on Waldenstrom’s Macroglobulinemia, which featured Dr. Steve Treon, Professor of Medicine at Harvard Medical School and Director of the Bing Center for WM at the Dana Farber Cancer Institute.

Steve Treon with hematologists in training at the Masterclass on WM at the Haematology Association of Ireland, Belfast. Fifty hematologists in training attended the Masterclass on Waldenstrom’s Macroglobulinemia held as part of the Annual Meeting of the Hematology Association of Ireland (HAI) in Belfast. Dr. Steve Treon of the Bing Center for WM at the Dana Farber Cancer Institute gave a State of the Art Keynote lecture on Friday, October 13, 2017 entitled “Genomic and Treatment Advances in Waldenstrom’s Macroglobulinemia”.

On a beautiful crisp fall day, October 14th, we were blessed to have Dr. Jorge Castillo, from the Bing Center of Dana Farber, come to speak with us in Denver about WM. He was fantastic! We had 62 patients and caregivers present to hear him, share a breakfast snack, and integrate the newly diagnosed people into our group! We are getting about 8-10 new patients each year and all of them love the camaraderie, the knowledge, the sharing of ideas and hope that our group provides. One of the new patients drove all the way from Santa Fe, NM to join us!

For those within the Los Angeles/Orange County areas, Dr Steven Treon will be lecturing on Updates in the Diagnosis and Treatment for Waldenstrom’s macroglobulinemia (WM) on Sunday, November 19th, 2017. If you are in the area and interested in attending, please RSVP to Marla Chao of the IWMF L.A./ Orange County support group. Click here for more details on this meeting.

For those within the San Diego, California area, Dr Steven Treon will be lecturing on Updates in the Diagnosis and Treatment for Waldenstrom’s macroglobulinemia (WM) on Saturday, November 18th, 2017. If you are in the area and interested in attending, please RSVP to Kathy Battle of the IWMF San Diego support group. Click here for more details on this meeting.

Clinical Trials

The Bing Center for Waldenstrom's Research at the Dana-Farber Cancer Institute is committed to providing comprehensive state-of-the-art treatment for Waldenstrom's Macroglobulinemia, including novel therapeutics, combination therapies, and immunotherapies. Our clinical trials are devoted to advancing the effectiveness of current treatment options for Waldenstrom's, while ensuring the highest standard of care.

One of our priorities is maintaining active clinical trials year round in an effort to constantly improve our understanding and continue to offer patients the most effective treatments for Waldenstrom's macroglobulinemia. All of our clinical trials are open through the Waldenstrom's Macroglobulinemia Clinical Trials Group, which is composed of over 20 major cancer centers around the world. By maintaining such an extensive contingent of collaborating centers, we hope to be better able to enroll patients in our trials without delay. Not only does the WMCTG allow more convenient patient access to treatment, but will also facilitate completion of clinical trials in a more timely manner.

New clinical trials are initiated only after drugs and other active agents are carefully screened through basic research studies and/or other successful experiences in other patient populations. The goals of all our clinical trials include increasing the number of patients entering into remissions, particularly complete remissions, as well as increasing the duration of these remissions.

All of our proposed clinical trials are approved by a Scientific Review Committee (SRC) and an Institutional Review Board (IRB) and are regulated through the Office For The Protection Of Research Subjects (OPRS) at the Dana-Farber Cancer Institute. The IRB serves to ensure that our trials comply with existing regulations of the FDA, Department of Health and Human Services (HHS) and the state's DPH for the protection of human subjects.

If you are interested in more information about a clinical trial or becoming a co-investigator on one of our trials, please contact either:

This email address is being protected from spambots. You need JavaScript enabled to view it. 617-632-5598

This email address is being protected from spambots. You need JavaScript enabled to view it. 617-632-3685

This email address is being protected from spambots. You need JavaScript enabled to view it. 617-582-8667